Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of trontinemab in early symptomatic Alzheimer's disease
CTR20254099Phase 3Active
- Sponsor
- Roche
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of trontinemab in Alzheimer's disease (AD), sponsored by Roche. Started Jan 2026; status: active.
02
Drugs
trontinemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on CTR20254099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254099.